{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:09:54Z","timestamp":1790507394974,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Korean government","award":["202013B14"],"award-info":[{"award-number":["202013B14"]}]},{"name":"The Korea National Research Foundation","award":["2020R1F1A106740"],"award-info":[{"award-number":["2020R1F1A106740"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10557-021-07170-6","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T11:02:41Z","timestamp":1615978961000},"page":"679-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding"],"prefix":"10.1007","volume":"36","author":[{"given":"So-Ryoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonil","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-6372","authenticated-orcid":false,"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Do","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seil","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"issue":"7","key":"7170_CR1","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1160\/TH16-11-0876","volume":"117","author":"GYH Lip","year":"2017","unstructured":"Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230\u20139.","journal-title":"Thromb Haemost"},{"issue":"9921","key":"7170_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"key":"7170_CR3","doi-asserted-by":"crossref","unstructured":"Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc 2017;6(2).","DOI":"10.1161\/JAHA.116.004517"},{"issue":"9","key":"7170_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1161\/CIRCULATIONAHA.117.031354","volume":"138","author":"EC O'Brien","year":"2018","unstructured":"O'Brien EC, Holmes DN, Thomas LE, et al. Prognostic significance of nuisance bleeding in anticoagulated patients with atrial fibrillation. Circulation. 2018;138(9):889\u201397.","journal-title":"Circulation"},{"issue":"12","key":"7170_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"7170_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"22","key":"7170_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"4","key":"7170_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"7170_CR9","doi-asserted-by":"publisher","first-page":"e0189495","DOI":"10.1371\/journal.pone.0189495","volume":"12","author":"SR Lee","year":"2017","unstructured":"Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GYH. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study. PLoS One. 2017;12(12):e0189495.","journal-title":"PLoS One"},{"issue":"3","key":"7170_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2015.05.002","volume":"149","author":"EW Chan","year":"2015","unstructured":"Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586\u201395.","journal-title":"Gastroenterology"},{"issue":"8","key":"7170_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/europace\/euy054","volume":"20","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231\u201342.","journal-title":"Europace"},{"issue":"6","key":"7170_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1053\/j.gastro.2016.08.054","volume":"151","author":"WA Ray","year":"2016","unstructured":"Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105\u201312.","journal-title":"Gastroenterology"},{"issue":"9","key":"7170_CR13","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","volume":"46","author":"KL Wang","year":"2015","unstructured":"Wang KL, Lip GYH, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015;46(9):2555\u201361.","journal-title":"Stroke"},{"key":"7170_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","volume":"180","author":"GYH Lip","year":"2015","unstructured":"Lip GYH, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol. 2015;180:246\u201354.","journal-title":"Int J Cardiol"},{"issue":"5","key":"7170_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","volume":"152","author":"NS Abraham","year":"2017","unstructured":"Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152(5):1014\u201322 e1.","journal-title":"Gastroenterology"},{"issue":"8","key":"7170_CR16","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/STROKEAHA.119.025536","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Kwon S, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019;50(8):2245\u20139.","journal-title":"Stroke"},{"issue":"21","key":"7170_CR17","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2018.17242","volume":"320","author":"WA Ray","year":"2018","unstructured":"Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320(21):2221\u201330.","journal-title":"JAMA"},{"issue":"3","key":"7170_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4166\/kjg.2020.76.3.108","volume":"76","author":"MK Joo","year":"2020","unstructured":"Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, et al. Clinical guidelines for drug-induced peptic ulcer, 2020 revised edition. Korean J Gastroenterol. 2020;76(3):108\u201333.","journal-title":"Korean J Gastroenterol"},{"issue":"6","key":"7170_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4166\/kjg.2020.75.6.322","volume":"75","author":"JS Kim","year":"2020","unstructured":"Kim JS, Kim BW, Kim DH, et al. Guidelines for non-variceal upper gastrointestinal bleeding. Korean J Gastroenterol. 2020;75(6):322\u201332.","journal-title":"Korean J Gastroenterol"},{"issue":"5","key":"7170_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4093\/dmj.2014.38.5.395","volume":"38","author":"SO Song","year":"2014","unstructured":"Song SO, Jung CH, Song YD, et al. Background and data configuration process of a nationwide population-based study using the Korean national health insurance system. Diabetes Metab J. 2014;38(5):395\u2013403.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"7170_CR21","first-page":"799","volume":"46","author":"SC Seong","year":"2017","unstructured":"Seong SC, Kim YY, Khang YH, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46(3):799\u2013800.","journal-title":"Int J Epidemiol"},{"key":"7170_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijcard.2017.02.039","volume":"236","author":"SR Lee","year":"2017","unstructured":"Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol. 2017;236:226\u201331.","journal-title":"Int J Cardiol"},{"issue":"2","key":"7170_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"5","key":"7170_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"issue":"11","key":"7170_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"key":"7170_CR26","unstructured":"Cho MS, Yun JE, Park JJ, et al. Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation [published online December 3, 2018]. Stroke."},{"issue":"11","key":"7170_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"7170_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","volume":"156","author":"YH Chan","year":"2019","unstructured":"Chan YH, Lee HF, See LC, et al. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest. 2019;156(3):529\u201343.","journal-title":"Chest"},{"issue":"3","key":"7170_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1440-1746.2009.06188.x","volume":"25","author":"KM Fock","year":"2010","unstructured":"Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol. 2010;25(3):479\u201386.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"7170_CR30","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/ajg.2010.324","volume":"105","author":"Z Li","year":"2010","unstructured":"Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol. 2010;105(12):2570\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"7170_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420\u20139.","journal-title":"Gastroenterology"},{"issue":"9","key":"7170_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.amjmed.2003.10.040","volume":"116","author":"GV Papatheodoridis","year":"2004","unstructured":"Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A, Hadziyannis SJ. Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med. 2004;116(9):601\u20135.","journal-title":"Am J Med"},{"issue":"11","key":"7170_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1055\/s-0032-1310006","volume":"44","author":"S Nahon","year":"2012","unstructured":"Nahon S, Hag\u00e8ge H, Latrive JP, et al. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy. 2012;44(11):998\u20131008.","journal-title":"Endoscopy"},{"issue":"11","key":"7170_CR34","doi-asserted-by":"publisher","first-page":"805","DOI":"10.7326\/M19-1795","volume":"171","author":"AN Barkun","year":"2019","unstructured":"Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med. 2019;171(11):805\u201322.","journal-title":"Ann Intern Med"},{"issue":"2","key":"7170_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019;157(2):403\u201312.","journal-title":"Gastroenterology."},{"issue":"1","key":"7170_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","volume":"145","author":"IL Holster","year":"2013","unstructured":"Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105\u2013112.e15.","journal-title":"Gastroenterology"},{"issue":"2","key":"7170_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/STROKEAHA.120.030761","volume":"52","author":"S Kwon","year":"2021","unstructured":"Kwon S, Lee SR, Choi EK, Lee E, Jung JH, Han KD, et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding. Stroke. 2021;52(2):511\u201320.","journal-title":"Stroke"},{"key":"7170_CR38","doi-asserted-by":"crossref","unstructured":"Anghel L, Sascau R, Trifan A, Zota IM, Statescu C. Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. J Clin Med 2020;9(5).","DOI":"10.3390\/jcm9051398"},{"key":"7170_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/DDDT.S203112","volume":"13","author":"S Lin","year":"2019","unstructured":"Lin S, Wang Y, Zhang L, Guan W. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Drug Des Devel Ther. 2019;13:1527\u201333.","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"7170_CR40","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","volume":"23","author":"KS Cheung","year":"2017","unstructured":"Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017;23(11):1954\u201363.","journal-title":"World J Gastroenterol"},{"issue":"19","key":"7170_CR41","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/eurheartj\/ehy802","volume":"40","author":"KL Wang","year":"2019","unstructured":"Wang KL, Lopes RD, Patel MR, et al. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019;40(19):1492\u2013500.","journal-title":"Eur Heart J"},{"key":"7170_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","volume":"60","author":"SR Lee","year":"2019","unstructured":"Lee SR, Lee YS, Park JS, et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. Yonsei Med J. 2019;60:277\u201384.","journal-title":"Yonsei Med J"},{"issue":"25","key":"7170_CR43","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","volume":"73","author":"SR Lee","year":"2019","unstructured":"Lee SR, Lee HJ, Choi EK, et al. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019;73(25):3295\u2013308.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7170_CR44","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2018.11.051","volume":"73","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Park CS, et al. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol. 2019;73(8):919\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7170_CR45","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","volume":"72","author":"SR Lee","year":"2018","unstructured":"Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol. 2018;72(8):838\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7170_CR46","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1161\/STROKEAHA.118.024264","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Han KD, et al. Non-vitamin K antagonist oral anticoagulants in Asian patients with supranormal renal function. Stroke. 2019;50(6):1480\u20139.","journal-title":"Stroke"},{"issue":"5","key":"7170_CR47","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1161\/STROKEAHA.118.024210","volume":"50","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Optimal rivaroxaban dose in Asian patients with atrial fibrillation and Normal or mildly impaired renal function. Stroke. 2019;50(5):1140\u20138.","journal-title":"Stroke"},{"key":"7170_CR48","doi-asserted-by":"crossref","unstructured":"Park J, Kwon S, Choi EK, et al. Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database. Int J Arrhythm. 2019;20(5).","DOI":"10.1186\/s42444-019-0005-0"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07170-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:09:57Z","timestamp":1657256997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07170-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7170"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07170-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"1 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SRL, SK, JHJ, KDH, SO: None.EKC: Research grant from Sanofi-Aventis, Chong Kun Dang, Daiichi-Sankyo, BMS\/Pfizer, Biosense Webster, and Skylabs.GYHL: Consultant for Bayer\/Janssen, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo. Speaker for Bayer, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees have been received personally.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}